

Jessica R Flynn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1586020/publications.pdf>

Version: 2024-02-01

67
papers

2,264
citations

361045

20
h-index

233125

45
g-index

67
all docs

67
docs citations

67
times ranked

3473
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia. <i>Cancer Discovery</i> , 2018, 8, 958-971.	7.7	594
2	Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 30-37.	0.8	239
3	Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma. <i>Blood Cancer Journal</i> , 2020, 10, 79.	2.8	137
4	A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer. <i>Cancer</i> , 2020, 126, 850-860.	2.0	116
5	Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations. <i>JCO Precision Oncology</i> , 2020, 4, 355-366.	1.5	93
6	High neutrophil-to-lymphocyte ratio (NLR) is associated with treatment failure and death in patients who have melanoma treated with PD-1 inhibitor monotherapy. <i>Cancer</i> , 2020, 126, 76-85.	2.0	92
7	DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality. <i>Blood Advances</i> , 2020, 4, 3024-3033.	2.5	75
8	Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies. <i>Blood Advances</i> , 2020, 4, 4669-4678.	2.5	64
9	Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy. <i>Journal of Clinical Oncology</i> , 2022, 40, 369-381.	0.8	60
10	Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells. <i>Blood Advances</i> , 2021, 5, 3397-3406.	2.5	59
11	A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response. <i>Nature Communications</i> , 2020, 11, 4168.	5.8	46
12	Long-term Cardiopulmonary Consequences of Treatment-Induced Cardiotoxicity in Survivors of ERBB2-Positive Breast Cancer. <i>JAMA Cardiology</i> , 2020, 5, 309.	3.0	46
13	MRI radiomic features are associated with survival in melanoma brain metastases treated with immune checkpoint inhibitors. <i>Neuro-Oncology</i> , 2019, 21, 1578-1586.	0.6	42
14	Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions. <i>Clinical Cancer Research</i> , 2021, 27, 2920-2927.	3.2	42
15	Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy. <i>Blood</i> , 2021, 138, 531-543.	0.6	42
16	Factors Affecting Oncologic Outcomes of 90Y Radioembolization of Heavily Pre-Treated Patients With Colon Cancer Liver Metastases. <i>Clinical Colorectal Cancer</i> , 2019, 18, 8-18.	1.0	31
17	Immune Checkpoint Inhibitor-Associated Diabetes: A Single-Institution Experience. <i>Diabetes Care</i> , 2020, 43, 3106-3109.	4.3	28
18	Analysis of pneumonitis and esophageal injury after stereotactic body radiation therapy for ultra-central lung tumors. <i>Lung Cancer</i> , 2020, 147, 45-48.	0.9	27

#	ARTICLE	IF	CITATIONS
19	Letermovir for Prevention of Cytomegalovirus Reactivation in Haploidentical and Mismatched Adult Donor Allogeneic Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 85.e1-85.e6.	0.6	25
20	Analysis of Toxic Effects With Antiangiogenic Agents Plus Stereotactic Body Radiation in Ultracentral Lung Tumors. <i>JAMA Oncology</i> , 2019, 5, 737.	3.4	24
21	The International Prognostic Index Is Associated with Outcomes in Diffuse Large B Cell Lymphoma after Chimeric Antigen Receptor T Cell Therapy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 233-240.	0.6	24
22	Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to age 60 with Philadelphia chromosome-negative acute lymphoblastic leukemia. <i>Haematologica</i> , 2021, 106, 2086-2094.	1.7	24
23	Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia. <i>Leukemia</i> , 2021, 35, 3268-3271.	3.3	21
24	Impact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 72.e1-72.e8.	0.6	21
25	Risk-based stratification of carcinomas concurrently involving the endometrium and ovary. <i>Gynecologic Oncology</i> , 2019, 152, 38-45.	0.6	18
26	Decreased Hand Motor Resting-State Functional Connectivity in Patients with Glioma: Analysis of Factors including Neurovascular Uncoupling. <i>Radiology</i> , 2020, 294, 610-621.	3.6	18
27	Daily Fractionation of External Beam Accelerated Partial Breast Irradiation to 40ÂGy Is Well Tolerated and Locally Effective. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 859-866.	0.4	17
28	DCE-MRI perfusion predicts pseudoprogression in metastatic melanoma treated with immunotherapy. <i>Journal of Neuro-Oncology</i> , 2020, 146, 339-346.	1.4	17
29	Perineural invasion as a risk factor for locoregional recurrence of invasive breast cancer. <i>Scientific Reports</i> , 2021, 11, 12781.	1.6	17
30	Enhanced Detection of Treatment Effects on Metastatic Colorectal Cancer with Volumetric CT Measurements for Tumor Burden Growth Rate Evaluation. <i>Clinical Cancer Research</i> , 2020, 26, 6464-6474.	3.2	16
31	Definitive maxillary obturator prosthesis: Timelines for fabrication and follow-up. <i>Special Care in Dentistry</i> , 2020, 40, 315-319.	0.4	14
32	10-Year Breast Cancer Outcomes in Women â‰¥35 Years of Age. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1007-1018.	0.4	14
33	Is Residual Nodal Disease at Axillary Dissection Associated with Tumor Subtype in Patients with Low Volume Sentinel Node Metastasis After Neoadjuvant Chemotherapy?. <i>Annals of Surgical Oncology</i> , 2021, 28, 6044-6050.	0.7	14
34	Occurrence, risk factors, and outcomes of bone cement implantation syndrome after hemi and total hip arthroplasty in cancer patients. <i>Journal of Surgical Oncology</i> , 2019, 120, 1008-1015.	0.8	12
35	Racial disparities in access to alternative donor allografts persist in the era of â€œdonors for allâ€. <i>Blood Advances</i> , 2022, 6, 5625-5629.	2.5	12
36	Regional Lymph Node Involvement Among Patients With De Novo Metastatic Breast Cancer. <i>JAMA Network Open</i> , 2020, 3, e2018790.	2.8	10

#	ARTICLE	IF	CITATIONS
37	A perioperative multidisciplinary care bundle reduces surgical site infections in patients undergoing synchronous colorectal and liver resection. <i>Hpb</i> , 2019, 21, 181-186.	0.1	8
38	The predictive role of preoperative and postoperative neutrophil-lymphocyte ratio in sarcomatoid renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 916-923.	0.8	8
39	Contralateral Prophylactic Mastectomy Use After Neoadjuvant Chemotherapy. <i>Annals of Surgical Oncology</i> , 2020, 27, 743-749.	0.7	8
40	Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers. <i>British Journal of Cancer</i> , 2022, 126, 889-898.	2.9	8
41	Universal Engraftment after Allogeneic Hematopoietic Cell Transplantation Using Cryopreserved CD34-Selected Grafts. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 697.e1-697.e5.	0.6	7
42	VTE Rates and Safety Analysis of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Lenalidomide-Dexamethasone (KRD) with or without Rivaroxaban Prophylaxis. <i>Blood</i> , 2019, 134, 1835-1835.	0.6	7
43	Risk of Contralateral Breast Cancer in Women with Ductal Carcinoma In Situ Associated with Synchronous Ipsilateral Lobular Carcinoma In Situ. <i>Annals of Surgical Oncology</i> , 2019, 26, 4317-4325.	0.7	6
44	Clinicopathologic features associated with survival after cytoreductive nephrectomy for nonclear cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 811.e9-811.e16.	0.8	6
45	Clinical implications of drug-induced liver injury in early-phase oncology clinical trials. <i>Cancer</i> , 2020, 126, 4967-4974.	2.0	6
46	Ablative radiation therapy for hepatocellular carcinoma is associated with reduced treatment- and tumor-related liver failure and improved survival. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 1743-1752.	0.6	6
47	Comparing outcomes of robotic versus open mesorectal excision for rectal cancer. <i>BJS Open</i> , 2021, 5, .	0.7	6
48	Tolerability of Breast Radiotherapy Among Carriers of ATM Germline Variants. <i>JCO Precision Oncology</i> , 2021, 5, 227-234.	1.5	5
49	Pharmacoresistant seizures and IDH mutation in low-grade gliomas. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab146.	0.4	5
50	Pretransplantation Cognitive Dysfunction in Advanced-Age Hematologic Cancers: Predictors and Associated Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1497-1504.	2.0	5
51	Patterns of Recurrence Among Higher-Risk Patients Receiving Daily External Beam Accelerated Partial-Breast Irradiation to 40 Gy in 10 Fractions. <i>Advances in Radiation Oncology</i> , 2020, 5, 27-33.	0.6	4
52	Preoperative CT predictors of survival in patients with pancreatic ductal adenocarcinoma undergoing curative intent surgery. <i>Abdominal Radiology</i> , 2021, 46, 1607-1617.	1.0	4
53	Should Postoperative Radiation for Long Bone Metastases Cover Part or All of the Orthopedic Hardware? Results of a Large Retrospective Analysis. <i>Advances in Radiation Oncology</i> , 2021, 6, 100756.	0.6	4
54	Intra- and inter-reader agreement of iRECIST and RECIST 1.1 criteria for the assessment of tumor response in patients receiving checkpoint inhibitor immunotherapy for lung cancer. <i>Lung Cancer</i> , 2021, 161, 60-67.	0.9	2

#	ARTICLE	IF	CITATIONS
55	Easix and Modified-Easix Are Early Predictors of Severe Cytokine Release Syndrome and Neurotoxicity in Patients Treated with Chimeric Antigen Receptor T Cells. <i>Blood</i> , 2019, 134, 1947-1947.	0.6	2
56	Automated Breast Density Measurements From Chest Computed Tomography Scans. <i>Journal of Medical Systems</i> , 2019, 43, 242.	2.2	1
57	Resource Utilization in Hospitalized Patients With Cancer From Hospice Decision to Discharge and Provider-Type Differences. <i>American Journal of Hospice and Palliative Medicine</i> , 2020, 37, 503-506.	0.8	1
58	The spinal distribution of metastatic renal cell carcinoma: Support for locoregional rather than arterial hematogenous mode of early bony dissemination. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 196.e9-196.e14.	0.8	1
59	TP53 and CD19-Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 710-710.	0.6	1
60	Clinical Impact of Bridging Therapy Prior to Commercial Chimeric Antigen Receptor (CAR) T-Cell Therapies for Relapsed/Refractory Lymphomas. <i>Blood</i> , 2020, 136, 1-2.	0.6	1
61	Symptoms, Surgical Events, and Length of Stay of Surgical Oncology Outpatients. <i>Journal of Perianesthesia Nursing</i> , 2022, , .	0.3	1
62	Assessment of Frailty Can Guide Decision Making for Utilization of Sentinel Lymph Node Biopsy in Patients with Thick Melanoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 9031-9038.	0.7	0
63	ASO Visual Abstract: Assessment of Frailty Can Guide Decision Making for Utilization of Sentinel Lymph Node Biopsy in Patients with Thick Melanoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 470-471.	0.7	0
64	Employing competing risks analysis in an aging population where many patients die from other causes. <i>Journal of Geriatric Oncology</i> , 2021, , .	0.5	0
65	Clinical Factors Associated with Improved Survival Following Allogeneic HSCT after CD19 CAR Therapy in Adult Patients with Relapsed B-ALL. <i>Blood</i> , 2019, 134, 1348-1348.	0.6	0
66	Comparing Gradings of Immune Effector Cells Toxicities: Application of Astct Consensus Grading System and Implications for Clinical Management. <i>Blood</i> , 2019, 134, 4458-4458.	0.6	0
67	Evaluation of Melphalan Exposure in Lymphoma Patients Undergoing BEAM and Autologous Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 485.e1-485.e6.	0.6	0